Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade

I. Vaněčková, L. Řezáčová, J. Kuneš, J. Zicha,

. 2016 ; 159 (-) : 127-34. [pub] 20160114

Language English Country Netherlands

Document type Journal Article

Grant support
NV15-25396A MZ0 CEP Register

AIMS: Chronic endothelin receptor A (ETA) blockade lowered blood pressure (BP) by decreasing angiotensin-dependent vasoconstriction and attenuating calcium influx. We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR). METHODS: Four-week-old TGR rats were fed with normal-salt diet and given either different renin-angiotensin system (RAS) blockers [angiotensin receptor blocker losartan, angiotensin converting enzyme inhibitor captopril, direct renin inhibitor aliskiren], or ETA blocker (atrasentan) alone, or a combination of atrasentan with RAS blockers for 4weeks. At the end of the study, basal BP and acute BP responses to sequential blockade of renin-angiotensin (RAS), sympathetic nervous (SNS), and nitric oxide (NO) systems were determined in conscious rats. Thereafter, BP responses to acute inhibition of nifedipine-sensitive calcium influx through voltage-dependent calcium channels (L-VDCC) were measured. KEY FINDINGS: All RAS blockers similarly decreased BP to normotension, their effects being mediated through substantially attenuated RAS-dependent and moderately decreased SNS-dependent vasoconstriction. Atrasentan alone partially lowered BP, while BP was normalized by combination of atrasentan with either RAS blocker. In combination therapies, BP lowering effects resulted from the attenuation of both RAS- and SNS-dependent vasoconstriction. Moreover, atrasentan-treated groups had substantially reduced NO-dependent vasodilation and significantly decreased calcium influx through L-VDCC. CONCLUSIONS: Although the BP-lowering effect of combined ETA and RAS blockades in TGR is predominantly dependent on the effects exerted by RAS blockade, further effects are attributable to decreased calcium influx due to chronic ETA blockade.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014161
003      
CZ-PrNML
005      
20170426113112.0
007      
ta
008      
170413s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.lfs.2016.01.020 $2 doi
035    __
$a (PubMed)26775568
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Vaněčková, Ivana $u Institute of Physiology AS CR, Prague, Czech Republic. Electronic address: ivanava@biomed.cas.cz.
245    10
$a Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade / $c I. Vaněčková, L. Řezáčová, J. Kuneš, J. Zicha,
520    9_
$a AIMS: Chronic endothelin receptor A (ETA) blockade lowered blood pressure (BP) by decreasing angiotensin-dependent vasoconstriction and attenuating calcium influx. We tested whether the addition of ETA blockade to renin-angiotensin system (RAS) blockade would have further effects on the principal vasoactive systems contributing to BP maintenance in Ren-2 transgenic rats (TGR). METHODS: Four-week-old TGR rats were fed with normal-salt diet and given either different renin-angiotensin system (RAS) blockers [angiotensin receptor blocker losartan, angiotensin converting enzyme inhibitor captopril, direct renin inhibitor aliskiren], or ETA blocker (atrasentan) alone, or a combination of atrasentan with RAS blockers for 4weeks. At the end of the study, basal BP and acute BP responses to sequential blockade of renin-angiotensin (RAS), sympathetic nervous (SNS), and nitric oxide (NO) systems were determined in conscious rats. Thereafter, BP responses to acute inhibition of nifedipine-sensitive calcium influx through voltage-dependent calcium channels (L-VDCC) were measured. KEY FINDINGS: All RAS blockers similarly decreased BP to normotension, their effects being mediated through substantially attenuated RAS-dependent and moderately decreased SNS-dependent vasoconstriction. Atrasentan alone partially lowered BP, while BP was normalized by combination of atrasentan with either RAS blocker. In combination therapies, BP lowering effects resulted from the attenuation of both RAS- and SNS-dependent vasoconstriction. Moreover, atrasentan-treated groups had substantially reduced NO-dependent vasodilation and significantly decreased calcium influx through L-VDCC. CONCLUSIONS: Although the BP-lowering effect of combined ETA and RAS blockades in TGR is predominantly dependent on the effects exerted by RAS blockade, further effects are attributable to decreased calcium influx due to chronic ETA blockade.
650    _2
$a zvířata $7 D000818
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a antagonisté endotelinového receptoru $x farmakologie $7 D065128
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a potkani transgenní $7 D055647
650    _2
$a receptor endotelinu A $x účinky léků $7 D044022
650    _2
$a renin $x genetika $x fyziologie $7 D012083
650    _2
$a renin-angiotensin systém $x účinky léků $7 D012084
655    _2
$a časopisecké články $7 D016428
700    1_
$a Řezáčová, Lenka $u Institute of Physiology AS CR, Prague, Czech Republic.
700    1_
$a Kuneš, Jaroslav $u Institute of Physiology AS CR, Prague, Czech Republic.
700    1_
$a Zicha, Josef $u Institute of Physiology AS CR, Prague, Czech Republic.
773    0_
$w MED00003147 $t Life sciences $x 1879-0631 $g Roč. 159, č. - (2016), s. 127-34
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26775568 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170426113431 $b ABA008
999    __
$a ok $b bmc $g 1200626 $s 974939
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 159 $c - $d 127-34 $e 20160114 $i 1879-0631 $m Life sciences $n Life Sci $x MED00003147
GRA    __
$a NV15-25396A $p MZ0
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...